Friday, Sep 5, 1997
Genentech Discontinues IGF-I Drug Development Effort in Diabetes
Research of IGF-I in other therapeutic areas continues
South San Francisco, Calif. -- September 5, 1997 -- Genentech, Inc. (NYSE: GNE) today announced that it has decided to discontinue the IGF-I drug development effort in Type I and Type II diabetes mellitus. The decision was based on the scope and extended timeframe of the clinical program that would be required to address potential concerns about diabetic retinopathy when using IGF-I in Type I and Type II diabetes mellitus.
Genentech is continuing its research and development program focused on other potential therapeutic uses of IGF-I. IGF-I was being developed for Type I and Type II diabetes mellitus in collaboration with F. Hoffmann La Roche, Ltd of Switzerland. Genentech remains committed to the development of potential drugs in the areas of endocrinology and metabolic disorders.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. The company has headquarters in South San Francisco and is traded on the New York Stock Exchange and Pacific Exchange under the symbol GNE.
# # #